Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 244

Results For "launch"

2437 News Found

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda
News | February 11, 2021

Indian Pharma market to grow to US$ 130 bn by 2030: Gowda

The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.


Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr
News | February 06, 2021

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.


Zydus eyes $6 bn market with strong COVID-19 portfolio
News | January 18, 2021

Zydus eyes $6 bn market with strong COVID-19 portfolio

With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business


Pan-India COVID-19 vaccination drive to cover 300,000 persons per day
Policy | January 15, 2021

Pan-India COVID-19 vaccination drive to cover 300,000 persons per day

This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.


Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.